Posted by Michael Wonder on 21 Feb 2020
Regulator OKs Pfizer's Vizimpro as first-line treatment of mutated lung cancer
20 February 2020 - Pfizer Korea said Thursday that the Ministry of Food and Drug Safety has approved Vizimpro (dacomitinib) as the first-line treatment for mutated lung cancer patients.
Patients with non-small cell lung cancer and epidermal growth factor receptor (EGFR)-mutated exon 19 or 21 deletions (19del and 21del) will be treated with Vizimpro in the initial stage.
The result of the comparison between the first-generation EGFR-tyrosine kinase inhibitors gefitinib and Vizimpro-administered groups through ARCHER1050 clinical trial showed Vizimpro was better than gefitinib.
